CNS Pharmaceuticals grants CTO 9,500 RSUs

Faulkner Eric reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Faulkner Eric reported acquisition or exercise transactions in this Form 4 filing.

CNS Pharmaceuticals granted Chief Technology Officer Eric Faulkner 9,500 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one share of common stock. The award was issued in connection with his employment.

The RSUs vest over time: 25% after six months, another 25% after twelve months, and the remaining 50% in twelve quarterly installments thereafter, provided he remains employed on each vesting date. This is a stock-based compensation grant rather than an open-market share purchase.

Insider Trade Summary

Grant/Award: 9,500 shares

Grant/Award 1 txn

Insider Faulkner Eric

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	9,500	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 9,500 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Company common stock.
2. F2. The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.
3. F3. Issued in connection with the reporting person's employment with the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CNSP report for Eric Faulkner?

CNS Pharmaceuticals granted Eric Faulkner 9,500 restricted stock units. These RSUs give him the right to receive an equal number of common shares, subject to a multi-year vesting schedule linked to his continued employment with the company.

How many CNSP restricted stock units did Eric Faulkner receive?

Eric Faulkner received 9,500 restricted stock units from CNS Pharmaceuticals. Each unit corresponds to one share of common stock, awarded at no purchase price as part of his employment-based equity compensation package and subject to time-based vesting conditions.

What is the vesting schedule for Eric Faulkner’s CNSP RSUs?

Faulkner’s RSUs vest 25% six months after the grant date, 25% twelve months after the grant date, and the remaining 50% in twelve quarterly installments. Vesting requires his continued employment with CNS Pharmaceuticals on each applicable vesting date.

Does Eric Faulkner have to pay for his CNSP restricted stock units?

He does not pay a purchase price for these restricted stock units, which were granted at a stated price of $0.00 per unit. The award functions as stock-based compensation tied to his role and continued employment with CNS Pharmaceuticals.

Are Eric Faulkner’s CNSP RSUs fully owned immediately?

They are not fully owned immediately, because the 9,500 RSUs vest over time. Faulkner gains actual shares only as portions vest according to the six-month, twelve-month, and subsequent quarterly schedule, contingent on continued employment with the company.

Is this CNSP insider transaction a stock purchase or a grant?

This transaction is a grant of restricted stock units rather than an open-market stock purchase. CNS Pharmaceuticals awarded 9,500 RSUs to Eric Faulkner as part of his employment compensation, with vesting conditions instead of a cash payment for the shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 05:02 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faulkner Eric

(Last) (First) (Middle)

C/O CNS PHARMACEUTICALS, INC.

100 WEST LOOP SOUTH, SUITE 900

(Street)

HOUSTON TX 77027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CNS Pharmaceuticals, Inc. [ CNSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/02/2026		A		9,500		(2)	03/02/2036	Common Stock	9,500	(3)	9,500	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Company common stock.

2. The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.

3. Issued in connection with the reporting person's employment with the Company.

	/s/ Christopher Downs, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.